Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: Implications for the pathobiology of mucositis

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 1, 2008, Pages 33-41

  Logan, Richard M ^a,b   Gibson, Rachel J ^c   Bowen, Joanne M ^c,d   Stringer, Andrea M ^c,d   Sonis, Stephen T ^e   Keefe, Dorothy M K ^c,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chemotherapy; Irinotecan; Mucositis; Nuclear factor B; Pro inflammatory cytokines

Indexed keywords

CYTOKINE; EOSIN; HEMATOXYLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRINOTECAN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; COLON; CONTROLLED STUDY; DARK AGOUTI RAT; DIARRHEA; DIGESTIVE SYSTEM; DISEASE SEVERITY; FEMALE; IMMUNOHISTOCHEMISTRY; INTESTINE CRYPT; INTESTINE VILLUS; JEJUNUM; MOUTH MUCOSA; MUCOSA INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TISSUE SECTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLON; COLORING AGENTS; CYTOKINES; DIARRHEA; DIGESTIVE SYSTEM; EOSINE YELLOWISH-(YS); FEMALE; FLUORESCENT DYES; GASTRIC MUCOSA; HEMATOXYLIN; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; JEJUNUM; MOUTH MUCOSA; MUCOSITIS; NF-KAPPA B; RATS;

EID: 42149113491     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0570-0     Document Type: Article

References (34)

1. Alimonti A, Gelibter A, Pavese I et al (2004) New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev 30:555-562
2. Anthony L, Bowen J, Garden A et al (2006) New thoughts on the pathobiology of regimen-related mucosal injury. Support Care Cancer 14:516-518
3. Bowen JM, Gibson RJ, Keefe DM et al (2005) Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37:56-62
4. Cool JC, Dyer JL, Xian CJ et al (2005) Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Hormone IGF Res 15:72-82
5. Elting LS, Cooksley C, Chambers MS et al (2003) The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531-1539
6. Gibson R, Keefe D (2006) Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Supportive Care in Cancer 1-11
7. Gibson RJ, Bowen JM, Inglis MRB et al (2003) Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 18:1095-1100
8. Gibson RJ, Cummins AG, Bowen JM et al (2006) Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. Asian Pacific J Clin Oncol 2:39-49
9. Gibson RJ, Keefe DM, Thompson FM et al (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47:2751-2757
10. Iyer L, King CD, Whitington PF et al (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854
11. Junqueira L, Carneiro J, Long J (2005) Basic histology, 11th edn. McGraw-Hill, Lange
12. Kawahara M (2006) Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations. Expert Opin Drug Saf 5:303-312
13. Keefe DM, Gibson RJ, Hauer-Jensen M (2004) Gastrointestinal mucositis. Semin Oncol Nurs 20:38-47
14. Keefe DMK (2004) Gastrointestinal mucositis: a new biological model. Support Care Cancer 12:6-9
15. Keefe DMK (2006) Mucositis guidelines: what have they acheived and where to from here? Support Care Cancer 14:489-491
16. Keefe DMK, Brealey J, Goland GJ et al (2000) Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47:632-637
17. Krajewska M, Wang HG, Krajewski S et al (1997) Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res 57:1605-13
18. Krajewska M, Zapata JM, Meinhold-Heerlein I et al (2002) Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 4:129-40
19. Krajewski S, Krajewska M, Reed JC (1996) Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res 56:2849-2855
20. Logan RM, Gibson RJ, Sonis ST et al (2007) Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43:395-401
21. Logan RM, Stringer AM, Bowen JM et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev. doi:10.1016/j.ctrv.2007.03. 001
22. Melo M, Brito G, Soares R et al. Role of cytokines (TNF-α, IL-1β and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemotherapy and Pharmacology. doi:10.1007/s00280-007-0534-4
23. Mocellin S, Rossi CR, Pilati P et al (2005) Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16:35-53
24. Nakamura K, Honda K, Mizutani T et al (2006) Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 12:4628-4635
25. Pico J-L, Avila-Garavito A, Naccache P (1998) Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3:446-451
26. Podolsky DK (2002) Inflammatory Bowel Disease. N Engl J Med 347:417-429
27. Scully C, Epstein J, Sonis S (2003) Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck 25:1057-70
28. Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39-43
29. Sonis ST (2002) The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with antineoplastic therapy. Crit Rev Oral Biol Med 13:380-390
30. Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995-2025
31. Stringer AM, Gibson RJ, Logan RM et al (2007) Chemotherapy-Induced diarrhoea is associated with changes in the luminal environment in the DA rat. Exp Biol Med 232:96-106
32. Tallman MN, Miles KK, Kessler FK et al (2007) The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy- camptothecin (SN-38)-induced gastrointestinal toxicity in rats. J Pharmacol Exp Ther 320:29-37
33. Wang L, Walia B, Evans J et al (2003) IL-6 Induces NF-{kappa}B Activation in the intestinal epithelia. J Immunol 171:3194-3201
34. Yeoh ASJ, Bowen JM, Gibson RJ et al (2005) Nuclear factor- kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Rad Oncol Biol Phys 63:1295-1303